Literature DB >> 10206305

Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood.

B M Brennan1, A Rahim, J A Adams, O B Eden, S M Shalet.   

Abstract

Bone mineral density (BMD), serum osteocalcin and type I collagen C-telopeptide (ICTP) were assessed in a cohort of 31 (16 males) adults who had received cranial irradiation in childhood as part of their treatment for acute lymphoblastic leukaemia (ALL). Markers of bone turnover were compared with those of 35 age and body mass index (BMI) matched young adults (18 male). Growth hormone status had previously been determined using an insulin tolerance test and arginine stimulation test. Eight patients were classified as severe growth hormone deficiency (group 1), 12 patients as growth hormone insufficient (group 2) and 11 patients as normal (group 3). Vertebral trabecular BMD, lumbar spine and femoral neck integral BMD and forearm cortical bone mineral content (BMC) was measured 17.8 (6.8-28.6) years after cranial irradiation and was expressed as Z (standard deviation) scores. There was a significant reduction in vertebral trabecular BMD (median Z score -1.25, P < 0.001), in lumbar spine integral BMD (median Z score -0.74, P = 0.001), in forearm cortical BMC (median Z score -1.35, P < 0.001), and less so in femoral neck integral BMD (median Z score -0.43, P = 0.03). There was no difference among the growth hormone status groups for the following BMD measurements: vertebral trabecular BMD, lumbar spine integral BMD or femoral neck integral BMD (P = 0.8, P = 0.96 and P = 0.4 respectively). There was only a marginal significant difference for BMD at the wrist between growth hormone status groups (P = 0.04). There was no correlation between the BMD measurements with time since or age at diagnosis and no difference in markers of bone turnover between patients and controls; median serum osteocalcin 13.3 and 12.0 ng ml (P = 0.7), respectively, and for ICTP 5.0 and 4.9 microg L (P = 0.67) respectively. In conclusion, there is a highly significant reduction in BMD in young adults following treatment for ALL in childhood. The reduction in BMD affects both trabecular and cortical bone but did not seem to be related to time since diagnosis, age at diagnosis, or current growth hormone status. Possible explanations include a direct effect of chemotherapy, steroids or both on bone during childhood and hence an effect on the accretion of bone mass. In view of the risk of fractures in patients with osteopenia, adults treated for ALL in childhood may be at an increased risk of bone fractures later in life irrespective of the underlying cause of the osteopenia and thus intervention should be considered.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10206305      PMCID: PMC2362787          DOI: 10.1038/sj.bjc.6690296

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Is postmenopausal bone loss an age-related phenomenon?

Authors:  K Thomsen; A Gotfredsen; C Christiansen
Journal:  Calcif Tissue Int       Date:  1986-09       Impact factor: 4.333

2.  Serum osteocalcin in the assessment of corticosteroid induced osteoporosis. Effect of long and short term corticosteroid treatment.

Authors:  A Peretz; J P Praet; D Bosson; S Rozenberg; P Bourdoux
Journal:  J Rheumatol       Date:  1989-03       Impact factor: 4.666

3.  Models of spinal trabecular bone loss as determined by quantitative computed tomography.

Authors:  J E Block; R Smith; C C Glueer; P Steiger; B Ettinger; H K Genant
Journal:  J Bone Miner Res       Date:  1989-04       Impact factor: 6.741

4.  Glucocorticoid-induced osteoporosis.

Authors:  D J Baylink
Journal:  N Engl J Med       Date:  1983-08-04       Impact factor: 91.245

5.  Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I.

Authors:  J M Tanner; R H Whitehouse; M Takaishi
Journal:  Arch Dis Child       Date:  1966-10       Impact factor: 3.791

6.  Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II.

Authors:  J M Tanner; R H Whitehouse; M Takaishi
Journal:  Arch Dis Child       Date:  1966-12       Impact factor: 3.791

7.  Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia.

Authors:  J M Halton; S A Atkinson; L Fraher; C Webber; G J Gill; S Dawson; R D Barr
Journal:  J Bone Miner Res       Date:  1996-11       Impact factor: 6.741

8.  Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model.

Authors:  G E Friedlaender; R B Tross; A C Doganis; J M Kirkwood; R Baron
Journal:  J Bone Joint Surg Am       Date:  1984-04       Impact factor: 5.284

9.  Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia.

Authors:  J M Chessells; C Bailey; S M Richards
Journal:  Lancet       Date:  1995-01-21       Impact factor: 79.321

10.  Precise measurement of vertebral mineral content using computed tomography.

Authors:  C E Cann; H K Genant
Journal:  J Comput Assist Tomogr       Date:  1980-08       Impact factor: 1.826

View more
  18 in total

1.  Significant 25-hydroxyvitamin D deficiency in child and adolescent survivors of acute lymphoblastic leukemia: treatment with chemotherapy compared with allogeneic stem cell transplant.

Authors:  Jill H Simmons; Eric J Chow; Elizabeth Koehler; Adam Esbenshade; Lesley-Ann Smith; Jean Sanders; Debra Friedman
Journal:  Pediatr Blood Cancer       Date:  2010-12-22       Impact factor: 3.167

2.  Fractures among long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Carmen L Wilson; Kimberley Dilley; Kirsten K Ness; Wendy L Leisenring; Charles A Sklar; Sue C Kaste; Marilyn Stovall; Daniel M Green; Gregory T Armstrong; Leslie L Robison; Nina S Kadan-Lottick
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

3.  Bone mineral density in survivors of childhood brain tumours.

Authors:  M Petraroli; E D'Alessio; E Ausili; A Barini; P Caradonna; R Riccardi; M Caldarelli; A Rossodivita
Journal:  Childs Nerv Syst       Date:  2006-10-13       Impact factor: 1.475

4.  Efficacy of the Survivor Health and Resilience Education (SHARE) program to improve bone health behaviors among adolescent survivors of childhood cancer.

Authors:  Darren Mays; Jessica Donze Black; Revonda B Mosher; Allison Heinly; Aziza T Shad; Kenneth P Tercyak
Journal:  Ann Behav Med       Date:  2011-08

Review 5.  Bone mineral density deficits and fractures in survivors of childhood cancer.

Authors:  Carmen L Wilson; Kirsten K Ness
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

6.  Bone mineral density in young adult survivors of acute lymphoblastic leukemia.

Authors:  Inas H Thomas; Janet E Donohue; Kirsten K Ness; Donald R Dengel; K Scott Baker; James G Gurney
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

Review 7.  Bone-mineral density deficits from childhood cancer and its therapy. A review of at-risk patient cohorts and available imaging methods.

Authors:  Sue C Kaste
Journal:  Pediatr Radiol       Date:  2004-02-12

Review 8.  Health behaviors, medical care, and interventions to promote healthy living in the Childhood Cancer Survivor Study cohort.

Authors:  Paul C Nathan; Jennifer S Ford; Tara O Henderson; Melissa M Hudson; Karen M Emmons; Jacqueline N Casillas; E Anne Lown; Kirsten K Ness; Kevin C Oeffinger
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

9.  Bone Loss in Pediatric Survivors of Acute Lymphoblastic Leukemia.

Authors:  Arzu Duygu Donmez; Pamir Isik; Semra Cetinkaya; Nese Yarali
Journal:  Eurasian J Med       Date:  2018-11-30

10.  Prevention of bone growth defects, increased bone resorption and marrow adiposity with folinic acid in rats receiving long-term methotrexate.

Authors:  Chia-Ming Fan; Bruce K Foster; Susanta K Hui; Cory J Xian
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.